It will be another three months before the US Food and Drug Administration (FDA) is ready to give its verdict on the drug ruxolitinib from Incyte. The review period for the drug ruxolitinib has been extended until Sept. 21, according a company press release.
Ruxolitinib is administered as a topical treatment for atopical dermatitis, and it is in the class of drugs known as JAK-inhibitors.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.